Monoclonal antibody D2-40, a new marker of lymphatic endothelium, reacts with Kaposi's sarcoma and a subset of angiosarcomas
Monoclonal antibody D2-40, a new marker of lymphatic endothelium, reacts with Kaposi's sarcoma and a subset of angiosarcomas
复制标题
DOI：
10.1038/modpathol.3880543
复制
发表时间：
2002-04-01
期刊：
影响因子：
7.5
通讯作者：
Marks, A
中科院分区：
文献类型：
--
作者：
Kahn, HJ;Bailey, D;Marks, A
卡波西肉瘤（Kaposi 'ssarcoma，KS）的组织起源是淋巴管内皮还是血管内皮，目前还存在争议. D2-40是一种新的单克隆抗体，针对Mr 40，000 O-连接的唾液酸糖蛋白，其与淋巴管内皮上的固定抗性表位反应。我们试图建立D2-40对正常组织中淋巴管内皮的选择性，并在一系列62个福尔马林固定和石蜡包埋的血管病变（包括KS）中将其反应性与广泛使用的血管内皮标志物CD 31的表达进行比较。在正常组织中，D2-40染色淋巴通道的内皮，但不染色血管的内皮，包括通过与血管内皮标记物PAL-E的反应性定义的动脉和毛细血管。在我们的血管病变系列中，D2-40染色淋巴管瘤（10/10），无争议的淋巴管来源的良性肿瘤，但不是血管来源的良性肿瘤或瘤样病变，包括血管瘤（0/10），血管球瘤（0/3），血管脂肪瘤（0/2），化脓性肉芽肿（0/2），血管畸形（0/2），血管外皮细胞瘤。（0/1）或血管内皮瘤（0/1）。D2-40染色了所有皮肤KS病例（24/24）的所有进展阶段，包括斑块、斑块和结节阶段，支持这种疾病起源于能够进行淋巴分化的细胞类型的概念。D2-40还染色了7个血管内皮细胞瘤中的3个，表明这些肿瘤的一个子集可以沿着淋巴管内皮细胞谱系经历至少部分分化，并且可以被分类为淋巴管内皮细胞瘤。与之相比，CD 31在所有良性和恶性血管病变中表达，除了血管球瘤（0/3）和淋巴管瘤（5/10），其中染色是不存在的。我们认为，D2-40是一个新的选择性标记的淋巴管内皮细胞在正常组织和血管病变，并在常规处理的组织标本研究良恶性血管疾病有价值。
There is controversy over the histogenesis of Kaposi's sarcoma (KS) from lymphatic or blood vessel endothelium. D2-40 is a novel monoclonal antibody to an Mr 40,000 O-linked sialoglycoprotein that reacts with a fixation-resistant epitope on lymphatic endothelium. We sought to establish the selectivity of D2-40 for lymphatic endothelium in normal tissues and compare its reactivity with the expression of the widely used vascular endothelial marker CD31 in a series of 62 formalin-fixed and paraffin-embedded vascular lesions including KS. In normal tissues, D2-40 stained the endothelium of lymphatic channels but not of blood vessels, including arteries and capillaries defined by reactivity with the blood vessel endothelial marker PAL-E. In our series of vascular lesions, D2-40 stained lymphangiomas (10/10), benign tumors of undisputed lymphatic origin, but not benign neoplasms or tumorlike lesions of blood vessel origin, including hemangiomas (0/10), glomus tumors (0/3), angiolipomas (0/2), pyogentic granulomas (0/2), vascular malformations (0/2), hemangiopericytoma. (0/1), or hemangioendothelioma (0/1). D2-40 stained all cases of cutaneous KS (24/24) at all stages of progression, including patch, plaque, and nodular stages, supporting the concept that this disease originates from a cell type capable of undergoing lymphatic differentiation. D2-40 also stained three of seven angiosarcomas, indicating that a subset of these tumors can undergo at least partial differentiation along the lymphatic endothelial lineage and could be classified as lymphangiosarcomas. In comparison, CD31 was expressed in all benign and malignant vascular lesions, except for glomus tumors (0/3) and 5/10 lymphangiomas, in which staining was absent We conclude that D2-40 is a new selective marker of lymphatic endothelium in normal tissues and vascular lesions and is valuable for studying benign and malignant vascular disorders in routinely processed tissue specimens.